Sona Nanotech Inc.

Recent News

  • Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing

    Halifax, Nova Scotia--(Newsfile Corp. - November 27, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has closed its private placement that was announced on October 18, 2023 with the issuance of 3,750,000 shares at $0.20 per share and 1,875,000 common share purchase warrants exercisable to purchase an additional common share of Sona at a price of $0.30 per share until November 24, 2025. (the "Financing"). Insiders subscribed...

    2023-11-27 8:59 AM EST
  • Sona Nanotech Arranges Brokered Private Placement Financing

    Halifax, Nova Scotia--(Newsfile Corp. - October 18, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that it plans to raise up to $750,000 through a brokered private placement (the "Financing") of up to 3,750,000 units of Sona (each, a "Unit") at $0.20 per Unit (the "Offering Price"). Each Unit will consist of one common share of Sona (a "Common Share") and one-half (1/2) of a common share purchase warrant (each whole...

    2023-10-18 8:36 AM EDT
  • Sona Provides Corporate Update on Operating Activities

    Halifax, Nova Scotia--(Newsfile Corp. - October 12, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology life sciences company with proprietary manufacturing technology for biocompatible gold nanorods ("GNRs"), is pleased to provide an update on the status of its current operating activities, notably the development of its Targeted Hyperthermia Therapy ("THT") therapy and its rapid bovine tuberculosis prototype test. Sona CEO, David Regan, commented, "Earlier this year, Sona developed a plan to...

    2023-10-12 1:21 PM EDT
  • Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

    Halifax, Nova Scotia--(Newsfile Corp. - September 11, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted Hyperthermia Therapy ("THT") technology in not only attenuating the development of colorectal, breast, and melanoma tumor models in mice but also in facilitating systemic immune responses. The study posits that...

    2023-09-11 8:50 AM EDT
  • Sona to Engage with Medical Experts and Payors to Inform Regulatory and Commercialization Strategies for Its 'THT' Cancer Therapy

    Halifax, Nova Scotia--(Newsfile Corp. - September 5, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce it has partnered with EXCITE International ("EXCITE"), a global network of senior specialist physicians, payors, health systems, and end-users, to help guide the development of Sona's Targeted Hyperthermia Therapy. Through this partnership with EXCITE, Sona will gain access to EXCITE's global network to help it align pre-clinical and clinical trial design and regulatory strategy with...

    2023-09-05 9:31 AM EDT
  • Sona Nanotech Grants Options

    Halifax, Nova Scotia--(Newsfile Corp. - July 11, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF), (the "Company") is pleased to announce that it has granted 900,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") of which 825,000 have been granted to a Directors and Officers. Each option is exercisable into one common share at a price of $0.25 per share. 600,000 options will vest at the rate of 25% every six months and 300,000 options...

    2023-07-11 8:50 AM EDT
  • New NCL Assessment of Sona's GNR Technology Highlights Process Improvement Success

    Halifax, Nova Scotia--(Newsfile Corp. - June 8, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has received the third set of results of an independent assessment of its proprietary gold nanorod nanoparticles from the U.S. National Cancer Institute's Nanotechnology Characterization Laboratory ("NCL"). In addition to running similar assessments to those that have been previously announced for contamination and endotoxin levels, this assessment included an analysis of the surfactant...

    2023-06-08 9:39 AM EDT
  • Sona Nanotech Selects Minnetronix to Engineer Its Next Generation Targeted Hyperthermia Cancer Therapy Light Device

    Halifax, Nova Scotia--(Newsfile Corp. - May 30, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy ("THT") for colorectal cancer, is pleased to announce the selection of Minnetronix Medical to engineer the next generation of its infrared light device. The device will be used in Sona's development of THT to transfer energy by way of infrared light to Sona's proprietary, biocompatible gold nanorods in tumors which will then...

    2023-05-30 8:19 AM EDT
  • Sona Nanotech Elects New Board Chair and is Awarded Patent

    Halifax, Nova Scotia--(Newsfile Corp. - May 18, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona"), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy for colorectal cancer, is pleased to announce the election as chair of the board, Mr. Mark Lievonen, CM, who joined the board of Sona in December 2020. Mr. Lievonen served as president of Sanofi Pasteur Limited from 1999 to 2016, during which time it became a billion-dollar enterprise in Canada, manufacturing...

    2023-05-18 8:41 AM EDT
  • Sona's Interest in Legacy Crescent Lake Lithium Property Sold to Midex Resources

    Halifax, Nova Scotia--(Newsfile Corp. - May 9, 2023) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that an agreement for the sale of its non-core interest in the Crescent Lake lithium property located in Ontario, Canada ("Property") to an arm's length party, Midex Resources Ltd. ("Midex"), has been finalized ("Midex Agreement" or "Transaction").The Property was acquired by Antler Gold Inc. ("Antler") from Sona in May 2019 pursuant to a property acquisition agreement...

    2023-05-09 9:00 AM EDT

Next »